Amgen Inc (AMGN)
Amgen Inc. is a biotechnology company that develops, manufactures, and markets human therapeutics worldwide. Its portfolio includes treatments for conditions such as rheumatoid arthritis, psoriasis, osteoporosis, skeletal-related events, cardiovascular risk reduction, immune thrombocytopenia, multiple myeloma, anemia, thyroid eye disease, gout, and certain cancers and hematologic disorders. The company sells its products to healthcare providers, including physicians, clinics, dialysis centers, hospitals, and pharmacies, and it relies on pharmaceutical wholesale distributors for distribution. Amgen also maintains collaboration arrangements with AstraZeneca, BeOne Medicines, UCB, Kyowa Kirin, and BeiGene tied to selected development and commercialization programs. Incorporated in 1980, Amgen is headquartered in Thousand Oaks, California, and its common stock is listed on the NASDAQ exchange under the symbol AMGN.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AMGN
|
$426.71
|
10.6% Upside
|
Fair
|
$387.69
|
0.5% Upside
|
Fair
|
Great
|
2.7%
|
November 3, 2026
|
23.5x
|
17.6x
|
5.4x
|
208.5 B
|
242.1 B
|
21.8%
|
99.7%
|
2.5
|
60.4%
|
116.4%
|
